TISIDB

Summary
Symbol	CREB3L2
Name	cAMP responsive element binding protein 3-like 2
Aliases	BBF2H7; TCAG_1951439; B-ZIB transcription factor; BBF2 human homolog on chromosome 7; FUS/BBF2H7 protein; ba ......
Chromosomal Location	7q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Endoplasmic reticulum membrane Single-pass type II membrane protein. Note=ER membrane resident protein. Upon ER stress, translocated to the Golgi apparatus where it is cleaved. The cytosolic N-terminal fragment (processed cyclic AMP-responsive element-binding protein 3-like protein 1) is transported into the nucleus. ; SUBCELLULAR LOCATION: Processed cyclic AMP-responsive element-binding protein 3-like protein 2: Nucleus. Note=Upon ER stress, translocated into the nucleus.
Domain	PF00170 bZIP transcription factor
Function	Transcription factor involved in unfolded protein response (UPR). In the absence of endoplasmic reticulum (ER) stress, inserted into ER membranes, with N-terminal DNA-binding and transcription activation domains oriented toward the cytosolic face of the membrane. In response to ER stress, transported to the Golgi, where it is cleaved in a site-specific manner by resident proteases S1P/MBTPS1 and S2P/MBTPS2. The released N-terminal cytosolic domain is translocated to the nucleus to effect transcription of specific target genes. Plays a critical role in chondrogenesis by activating the transcription of SEC23A, which promotes the transport and secretion of cartilage matrix proteins, and possibly that of ER biogenesis-related genes (By similarity). In a neuroblastoma cell line, protects cells from ER stress-induced death (PubMed:17178827). In vitro activates transcription of target genes via direct binding to the CRE site (PubMed:17178827).

> Gene Ontology [ TOP ]
Biological Process	GO:0001501 skeletal system development GO:0002062 chondrocyte differentiation GO:0006888 ER to Golgi vesicle-mediated transport GO:0006986 response to unfolded protein GO:0030968 endoplasmic reticulum unfolded protein response GO:0034620 cellular response to unfolded protein GO:0034976 response to endoplasmic reticulum stress GO:0035966 response to topologically incorrect protein GO:0035967 cellular response to topologically incorrect protein GO:0048193 Golgi vesicle transport GO:0051216 cartilage development GO:0061448 connective tissue development
Molecular Function	GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0000987 core promoter proximal region sequence-specific DNA binding GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0001159 core promoter proximal region DNA binding GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding GO:0035497 cAMP response element binding
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04022 cGMP-PKG signaling pathway hsa04024 cAMP signaling pathway hsa04151 PI3K-Akt signaling pathway hsa04152 AMPK signaling pathway hsa04261 Adrenergic signaling in cardiomyocytes hsa04668 TNF signaling pathway hsa04725 Cholinergic synapse hsa04728 Dopaminergic synapse hsa04911 Insulin secretion hsa04915 Estrogen signaling pathway hsa04916 Melanogenesis hsa04918 Thyroid hormone synthesis hsa04922 Glucagon signaling pathway hsa04962 Vasopressin-regulated water reabsorption
Reactome	-

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04022 cGMP-PKG signaling pathway
hsa04024 cAMP signaling pathway
hsa04151 PI3K-Akt signaling pathway
hsa04152 AMPK signaling pathway
hsa04261 Adrenergic signaling in cardiomyocytes
hsa04668 TNF signaling pathway
hsa04725 Cholinergic synapse
hsa04728 Dopaminergic synapse
hsa04911 Insulin secretion
hsa04915 Estrogen signaling pathway
hsa04916 Melanogenesis
hsa04918 Thyroid hormone synthesis
hsa04922 Glucagon signaling pathway
hsa04962 Vasopressin-regulated water reabsorption

Reactome

Summary
Symbol	CREB3L2
Name	cAMP responsive element binding protein 3-like 2
Aliases	BBF2H7; TCAG_1951439; B-ZIB transcription factor; BBF2 human homolog on chromosome 7; FUS/BBF2H7 protein; ba ......
Chromosomal Location	7q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between CREB3L2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	CREB3L2
Name	cAMP responsive element binding protein 3-like 2
Aliases	BBF2H7; TCAG_1951439; B-ZIB transcription factor; BBF2 human homolog on chromosome 7; FUS/BBF2H7 protein; ba ......
Chromosomal Location	7q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of CREB3L2 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	logFC: 0.98; FDR: 0.021200	Sensitive to T cell-mediated killing
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	CREB3L2
Name	cAMP responsive element binding protein 3-like 2
Aliases	BBF2H7; TCAG_1951439; B-ZIB transcription factor; BBF2 human homolog on chromosome 7; FUS/BBF2H7 protein; ba ......
Chromosomal Location	7q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of CREB3L2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.219	0.527
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.25	0.902
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.563	0.712
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.188	0.543
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.125	0.955
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.27	0.921
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.251	0.564
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.064	0.973
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.636	0.762
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.589	0.613
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.095	0.537
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.049	0.613

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of CREB3L2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	2.7	4.7	0.294
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	3.4	4	0.587
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	0	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	0	7.7	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	0	11.1	0.36
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	0	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	CREB3L2
Name	cAMP responsive element binding protein 3-like 2
Aliases	BBF2H7; TCAG_1951439; B-ZIB transcription factor; BBF2 human homolog on chromosome 7; FUS/BBF2H7 protein; ba ......
Chromosomal Location	7q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CREB3L2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	CREB3L2
Name	cAMP responsive element binding protein 3-like 2
Aliases	BBF2H7; TCAG_1951439; B-ZIB transcription factor; BBF2 human homolog on chromosome 7; FUS/BBF2H7 protein; ba ......
Chromosomal Location	7q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CREB3L2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CREB3L2. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	CREB3L2
Name	cAMP responsive element binding protein 3-like 2
Aliases	BBF2H7; TCAG_1951439; B-ZIB transcription factor; BBF2 human homolog on chromosome 7; FUS/BBF2H7 protein; ba ......
Chromosomal Location	7q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CREB3L2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	CREB3L2
Name	cAMP responsive element binding protein 3-like 2
Aliases	BBF2H7; TCAG_1951439; B-ZIB transcription factor; BBF2 human homolog on chromosome 7; FUS/BBF2H7 protein; ba ......
Chromosomal Location	7q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of CREB3L2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	CREB3L2
Name	cAMP responsive element binding protein 3-like 2
Aliases	BBF2H7; TCAG_1951439; B-ZIB transcription factor; BBF2 human homolog on chromosome 7; FUS/BBF2H7 protein; ba ......
Chromosomal Location	7q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between CREB3L2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	CREB3L2
Name	cAMP responsive element binding protein 3-like 2
Aliases	BBF2H7; TCAG_1951439; B-ZIB transcription factor; BBF2 human homolog on chromosome 7; FUS/BBF2H7 protein; ba ......
Chromosomal Location	7q34
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting CREB3L2 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse CREB3L2